TCGA-G2-AA3D-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 70.26938239
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- CHOLESTEROL_HOMEOSTASIS+0.220
- SPERMATOGENESIS+0.190
- PEROXISOME+0.120
- XENOBIOTIC_METABOLISM+0.110
- BILE_ACID_METABOLISM+0.100
- G2M_CHECKPOINT+0.080
- APICAL_SURFACE+0.060
- E2F_TARGETS+0.050
- ESTROGEN_RESPONSE_EARLY+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- TNFA_SIGNALING_VIA_NFKB-0.480
- ALLOGRAFT_REJECTION-0.450
- ANGIOGENESIS-0.450
- TGF_BETA_SIGNALING-0.410
- HYPOXIA-0.390
- IL2_STAT5_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.390
- APOPTOSIS-0.370
- WNT_BETA_CATENIN_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-QK-AA3J-01A-11R-A39I-07 | — | — | 0.881 |
| 2 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.863 |
| 3 | TCGA-ZF-AA4X-01A-11R-A38B-07 | — | — | 0.862 |
| 4 | SRR1478096 | GTEX | — | 0.850 |
| 5 | SRR8943037 | — | — | 0.850 |
| 6 | SRR8943043 | — | — | 0.849 |
| 7 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.848 |
| 8 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.846 |
| 9 | MDT-AP-2068 | Med | Medulloblastoma | 0.843 |
| 10 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |